Blog | BioInformant

Revolutionizing Hair Regrowth with Stem Cells and Regenerative Treatments

January 16, 2026 By Cade Hildreth, Founder & President Leave a Comment

^{Sponsored Content: This article contains sponsored content mentioned, as noted below. Most of this article is BioInformant editorial content.}*

The quest for a full head of hair has captivated humankind for centuries. Countless individuals, plagued by hair loss and thinning, have sought effective remedies to restore their once-abundant tresses. In recent years, scientific advancements in the field of regenerative medicine have sparked hope with the potential use of stem cells and other innovative treatments for hair regrowth. This article delves into the exciting possibilities offered by these therapies, shedding light on their mechanisms and exploring their current status in the realm of hair restoration. [Read more…]

Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in U.S.

January 15, 2026 By BioInformant Team Leave a Comment

Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications

PRINCETON, N.J. and DAVIE, Fla. and TEL AVIV, Israel, Jan. 7, 2026 – Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora’s novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States. [Read more…]

Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience

January 15, 2026 By BioInformant Team Leave a Comment

CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. [Read more…]

Can Stem Cells Treat an ACL Tear or Torn Meniscus?

January 15, 2026 By BioInformant Team 1 Comment

Can stem cell therapy be used to treat an ACL tear or torn meniscus? While these injuries are traditionally treated using invasive orthopedic surgeries, stem cells are now emerging as a therapeutic alternative.

In this article:

Stem Cells for ACL or Meniscus Tear
Are Stem Cell Treatments for Knees Safe
RegeneVive Review
Regenexx Review
Stem Cell Institute Review
Can Stem Cell Therapy Regrow Meniscus
Does Stem Cell Therapy for Knees Work

[Read more…]

Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies

January 13, 2026 By BioInformant Team Leave a Comment

Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]

*Sponsored Content: This article contains sponsored content mentioned, as noted below. Most of this article is BioInformant editorial content.

Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications

^{Sponsored Content: This article contains sponsored content mentioned, as noted below. Most of this article is BioInformant editorial content.}*